Somerset Lifesciences Inc. Agrees to Pay $4M to Resolve Allegations of Causing Medicare to Pay Claims for its Mislabeled Generic Drug
“Today’s resolution underscores the Department’s commitment to safeguarding federal healthcare programs,” said
@AAGShumate. “When companies cause Medicare to pay for products that are not eligible for coverage, the Department will act decisively to remedy that misconduct.”
🔗: